An ophthalmic formulation for preventing and treating
cataracts contains an active substance for treating eye diseases and a pharmaceutically acceptable carrier or
excipient. The active substance is oxidized
cholesterol, including
lanosterol or 25-hydroxycholesterol; the pharmaceutically acceptable carrier or
excipient contains a surfactant, a
tackifier, a cosolvent, and a
solvent; the content of the oxidized
cholesterol in the formulation is 0.01-5 mg / mL; and the
mass ratio of the surfactant, the
tackifier, the cosolvent, and the oxidized
cholesterol is (1-300):(1-100):(100-3000):1, with the balance being the
solvent. Upon
eye drop administration, the formulation can cause the active substance to be selectively enriched in the lens of a laboratory animal to accurately exert the effect of treating
cataracts. The active substance is not distributed in the
aqueous humor and the vitreous body, thereby avoiding toxic and side effects on other eye tissue and the
whole body.